'Astrazeneca' presentation slideshows

LIPID MODIFICATION IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE: Clinical, Public Health and Ethical Chall

LIPID MODIFICATION IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE: Clinical, Public Health and Ethical Challenges . Charles H Hennekens, MD, DrPH Sir Richard Doll Research Professor of Medicine Charles E. Schmidt College of Medicine Florida Atlantic University

1.02k views • 83 slides

Big Pharma - The Way Forward

403 views • 28 slides

PARP Inhibitors for the treatment of MPNST

Sarcoma Research Laboratory University of Texas, MD Anderson Cancer Center. PARP Inhibitors for the treatment of MPNST.

470 views • 22 slides

CAFE TRIAL

CAFE TRIAL. Ron Beasley, PharmD Candidate Preceptor: Soheyla M ahdavian, PharmD. CAFE TRIAL. C omparison of A typicals in F irst E pisode of p sychosis

290 views • 15 slides

Anticipation in Canada since Sanofi

295 views • 15 slides

Driver licensing and Aboriginal people

Driver licensing and Aboriginal people. Important road safety issue understanding of road rules and appropriate level of driving skills Important contributor to other key drivers of health and welfare enables access to employment and education

275 views • 13 slides

Using Weibull Model to Predict the Future: ATAC Trial

Using Weibull Model to Predict the Future: ATAC Trial. Anna Osmukhina , PhD Principal Statistician, AstraZeneca April 15, 2010.

204 views • 9 slides

European Prostate Cancer Therapeutics Market

148 views • 5 slides

AstraZeneca inks $6.9-bn breast, gastric cancer therapy deal with Daiichi

Read more about AstraZeneca inks $6.9-bn breast, gastric cancer therapy deal with Daiichi on Business Standard. AstraZeneca said the transaction won't impact earnings this year but will make a 'significant contribution' by 2023

28 views • 2 slides

Common Technical Document

Common Technical Document. AstraZeneca strongly supports CTD and seeks to utilise it as soon as is feasible. In deciding upon strategies for implementation, AstraZeneca would ask that the following points be taken into account :.

763 views • 1 slides

Annual General Meeting and Presentation Supper

163 views • 1 slides

Unplanned 30-Day Readmission Risk Among Patients with Acute Myocardial Infarction:

Table 2. Timing of ADP receptor inhibitor switch. Unplanned 30-Day Readmission Risk Among Patients with Acute Myocardial Infarction: a Report from TRANSLATE-ACS Connie N. Hess, MD 1 ; Tracy Y. Wang, MD, MHS 1 ; Lisa McCoy 1 ; Emily Honeycutt 1 ;

144 views • 1 slides